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REVIEW
Abstract—Clinical experience and basic science studies show
that Negative Pressure Wound Therapy (NPWT) is a promising
yet still under-used treatment method for patients with diabetic
foot syndrome. Despite its advantages, it may carry the risk of
serious side effects if the indications and contraindications are not
strictly observed. The aim of this article is to discuss myths and
facts about NPWT in conditions such as inadequate blood supply,
insufficient wound debridement, osteomyelitis or the necessity to
monitor laboratory parameters during the therapy. We will try
to define the optimal conditions for NPWT in order to obtain
better results and eliminate the risk of side effects.
Keywords—negative pressure wound therapy, vacuum ther-
apy,diabetic foot syndrome, diabetic ulcer
I. INTRODUCTION
D IABETIC foot syndrome (DFS) is a growing concernof modern medicine. It affects approximately 10–15%
of patients with type 2 diabetes (DM). This number is con-
sistently growing due to aging population and decreasing the
age of DM onset.1 Chronicity and natural predisposition to
wound infection in DFS determine the need for optimization
of the healing process. NPWT is effective in restoring moisture
balance in the wound bed, improving blood supply to damaged
tissues and eliminating the source of infection. It promotes the
formation of granulation tissue and finally accelerates wound
closure.2 DFS can be the cause of generalized infection and
even death of the patient. The most common life-threatening
complication is amputation. 5-year mortality rate after first
amputation is approx. 40%, which is similar to e.g. kidney
cancer mortality rate.3, 4
II. HOW DO THE GUIDELINES PRIORITIZE NPWT
IN THE TREATMENT OF DFS?
Standardized indications for NPWT in the DFS were pub-
lished recently in 2011 by NPWT-Expert Panel. They define
two main goals of DFS patients’ treatment.5 The primary
aim is the wound closure. Of all indications, the strongest
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recommendation is given to NPWT as a second-line treatment
of non-healing wounds and managing surgical wounds of 2nd
and 3rd grade in Texas Scale6 in DFS without ischemia. The
secondary goal is stopping the wound progression (degree of
recommendation B). The guidelines emphasize the importance
of NPWT as a method that fulfils the task of preventing the
amputation and re-amputation of the limb and has an indirect
influence on mortality of patients after amputations. It should
be considered in every patient with DFS. Before the treatment,
however, one should carefully analyse all the contraindications
and answer some key questions about the patient. These issues
will be discussed below.
A. Can NPWT be used in patients with neuro-ischemic DFS?
NPWT increases levels of TGF-β and PDGF, accelerates
the formation of granulation tissue and amplifies angiogen-
esis.7 Xia observed an increase of VEGF, EGF, PDGF and
angiotensin-2 concentration and reduction of fibroblast growth
factor level.8 Furthermore, NPWT mechanically contributes
to optimizing the perfusion at a negative pressure of −125
mmHg.
According to Timmers, the hypoperfusion occurs only at a
negative pressure below −500 mmHg.9 Kasai draws the hy-
pothesis that the suction pressure contributes to the occlusion
of the majority of the capillary vessels located on the edge of
the wound.10 Present studies show that even negative pressure
of −125 mmHg will produce a zone of increased perfusion
(2.5 cm) as well as ischemic zone within and immediately
around (0.5 cm) the edges of the wound. Temporary ischemia
can promote healing through hypoxia inducible factor (HIF)
production.11 Borgquist demonstrates that using lower levels
of negative pressure of −80 mmHg does not have an influence
on the therapeutic effect.12 In patients with impaired blood
flow in the lower limb arteries, optimal negative pressure
levels can cause the necrosis in the wound edges.13, 14 This
is because patients with an ankel-brachial index (ABI) of less
than 0.6 should not be considered for the NPWT. The TpO2
measurement should be the diagnostic method of choice, but
it is not widely available. Levels below 30 mmHg limit the
use of NPWT. Every patient with clinically significant arterial
occlusions should first undergo revascularization procedures.
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B. Can we substitute debridement by NPWT?
The proper wound treatment requires a comprehensive
approach. The guidelines for wound management were pub-
lished in 2002 by European Wound Management Association
(EWMA). According to the TIME concept, comprehensive
care of wound bed consists of tissue management, control
of infection and inflammation, moisture balance and advance-
ment of the epithelial edge of the wound.15 NPWT fits per-
fectly into the above-mentioned strategy, which is extremely
important in the treatment of DFS ulceration. It should be
noted, that proper preparation and debridement of the wound
is essential before the treatment. Removal of necrotic tissue
and bacterial burden helps to define the size and condition
of the wound. We emphasize that in neuropathic ulcers the
superficial, hyperkeratotic layer can cover the infected tissues.
Deep debridement can reveal bare bone fragments, thus limit-
ing the use of traditional NPWT systems. Minimization of
the infection potential and prolonged inflammatory process
induced by pro-inflammatory factors from necrotic tissue
contributes to the optimization of the treatment conditions.
To sum up, NPWT sticks to the TIME concept, provided that
the deep debridement before the treatment is achieved.
C. How does NPWT system control the presence of infection
signs in the wound?
The amount of exudate in chronic wounds is increased and
leads to maceration of surrounding tissues. The composition
of the fluid is also imbalanced, with increased level of pro-
inflammatory factors. Chronic inflammation in the wound bed
is expressed through the high levels of TNF-α, IL-1β and
IL-6 in the exudate.16–18 It is proven that an increase in
the level of Il-1 and a reduction of TGF-β induces higher
expression of metalloproteinases (MMP). The levels of MMP
are increased in diabetic ulcers. Many researchers have ob-
served a significant prevalence of MMP-9 and MMP-2.19–21
The healing and remodelling processes can be inhibited by an
inadequate ratio of metalloproteinases to their tissue inhibitors
(TIMP).22 Hyperglycaemia, often accompanying diabetic foot
ulcers, leads to further development of inflammation through
the activation of mitogen-activated protein kinase and protein
kinase C, as well as oxidative stress and AGEs.23 Removal of
an excess volume of exudate and MMP in NPWT is likely to
increase the healing rate and tissue regeneration.24
The additional benefit in wounds associated with abundant
exudate is the physical decompression of the pressure on the
wound bed. According to Young, in 4 days of NPWT swelling
was decreased by 43%. This can be explained by macro-
deformation of the tissues, leading to reverse tissue expansion
and also altering the blood flow in the wound vessels.25
Numerous studies show that the addition of exudate from
chronic wounds to the cell culture inhibits the proliferation
of the cells.18, 26, 27
Mechanical suction in NPWT reduces swelling and also
allows controlling the infection by decreasing number of
microorganisms and dead cells, which can cause prolonged
inflammation and lack of wound healing.
NPWT is indicated especially in wounds involving extensive
exudate that is difficult to manage. "Dry wounds” (the amount
of aspirate 20–50 mL/day) require special care and considering
a method other than NPWT.
D. Does the exudate removal reduce the amount of infectious
agent in the wound?
A clinical infection in the wound bed and adjacent tissues
is a major problem leading to persistent inflammation and
significantly delayed healing process. Undoubtedly, improving
blood circulation and function of inflammatory cells in NPWT
contributes to the proper management of infected wounds.
This is why patients with grade I and II in PEDIS scale can
benefit the most from using NPWT. According to the research
by Moues and Weed, in animal model of chronic wounds,
the number of bacterial colonies has not diminished during
NPWT.28, 29 The bacterial profile, however, has changed from
anaerobic to aerobic G+ species. According to studies, S. au-
reus is the dominating microorganism in ulcers treated with
vacuum therapy.29 It appears that the colonization by S. aureus
may have a positive effect on the wound healing.30, 31 There
is a discussion on the possible negative effect of foams used
in NPWT and their role in spreading the infection, which may
result from the problem of foam contamination.32 NPWT-EP
recommends repetitive changes of the NPWT dressings every
2 or 3 days. Special attention should be given to signs of
infection and fibres of dressing left in the wound. Foam or
gauze dressings can be used. According to recent publications,
both types of dressing are equally effective at delivering
negative pressure, wound contraction and stimulation of blood
flow at the wound edge. The advantage of gauze is its fast
application and easy adjustment to the surface of wounds. In
contrast to foam dressing, application of gauze may be quite
challenging in the case of a complex wound with several layers
and uneven bed.33 However, studies have documented an in-
growth of granulation tissue into the cells of the open cell
polyurethane foam. This may cause patients to experience pain
during dressing changes and disturb the re-epithelialisation
process.34–37
Proper wound healing by granulation may be inhibited by
the remaining fibres of the dressing. Using wound contact lay-
ers helps eliminate in-growth and pain.38 The NPWT method
is based on the induction of negative pressure in purified
wounds and it is natural that after discontinuation of drainage
the production of exudate may be increased. The sponge used
in NPWT should be prepared with special attention in order
to avoid covering healthy skin with the dressing. Too large
sponge may damage the healthy skin around the wound and
increase the risk of wet necrosis or fistula formation. Local
allergic reactions were also observed in NPWT patients, man-
ifesting as pruritus or contact eczema (e.g. contact dermatitis
caused by the film covering the sponge). It is only rarely
that the therapy has to be discontinued, especially in cases
of uncontrolled bleeding or a blood clot formation under the
dressing.
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E. Is osteomyelitis a contraindication for NPWT in DFS?
The development of inflammation and infection during the
NPWT may be overlooked. Anatomy of the foot allows rapid
spread of infection along the muscles and tendons.39 Special
attention should be given to osteomyelitis, which requires
chronic anti-microbial therapy or surgical resection. The risk
of osteomyelitis increases when the ulcer is not healing after
six weeks of proper therapy. Clinically, osteomyelitis can be
confirmed in the case of a deep, extensive ulceration when the
bone is visible at the bottom of the wound bed or when the
PTBT test is positive. The local ischemia caused by NPWT
could increase the area of infection when osteomyelitis is
present. In case of extensive infections (defined as grade 3
and 4 on a PEDIS scale), standard NPWT systems should not
be used. Before the NPWT, osteomyelitis needs to be ruled
out in order to prevent bacterial translocation from the wound
bed to bone.40 In patients with osteomyelitis, NPWT should
not be initiated until the appropriate antibiotic therapy and the
wound debridement have been performed, including removal
of infected bone if necessary.41
F. What laboratory parameters should be monitored during
NPWT?
Chronic wounds are conducive to developing anaemia.
Patients with DFS are extremely prone to ischemia. Physicians
should take care that the levels of haemoglobin stay optimal
and not fall below 10 g/dL. Emphasis on this parameter
reduces the likelihood of ischemic episodes and allows the
wound to heal properly. Patients on chronic anticoagulant
therapy, as well as patients with active bleeding in medical
history or bleeding disorders, require increased attention due
to the bleeding risk. However, the use of anticoagulants is not
a contraindication to NPWT.
G. Does NPWT system induce neoplastic process?
It should be noted that increased perfusion may be a prob-
lem in wounds with neoplastic lesions. To minimize the risk of
uninhibited tumour growth, patients with atypical ulcerations
and malignancies in other organs should be screened for the
presence of neoplastic cells in wound bed before the NPWT
treatment.42
III. CONCLUSIONS
NPWT reduces the number of required dressing changes
and allows the patient to rest.43 Fewer interventions in the
wound decrease the likelihood of contamination.44 Moreover,
the change of dressing used in vacuum therapy is less painful
for patients. At the beginning of the therapy, however, patients
could feel pain or discomfort due to the negative pressure. The
vacuum stimulates the growth of new tissue and epithelializa-
tion. It contributes to the well-being of the patient since the
first results are soon visible.45 In addition, negative pressure
continuously removes the excess of exudate, which reduces
odour from the wound.46 However, NPWT must be applied
for at least 22 hours a day to yield such results.
NPWT enables the concomitant rehabilitation, which short-
ens the period of treatment.47
So far, NPWT was considered an expensive technical nov-
elty but it has a significant advantage in terms of relative cost-
effectiveness in comparison with conventional therapy. Care
for patients with active ulcer multiplies the expenses incurred
by the health care system (5.4 times compared to patients
with isolated DM).48 Wound closure reduces the amount of
spending for proper wound management. It should be noted
that the treatment of superficial infection is approx. 11 times
cheaper than in the case of generalized infection which often
results in the need for amputation. Reduced frequency of
dressing changes, faster wound healing and the possibility of
mobilization of patients at the same time, lowers the cost of
vacuum treatment compared to standard therapy.49
Growing knowledge on the mechanism of action of standard
NPWT increases the safety of this therapy in patients with
DFS. The best results of NPWT are observed in patients with
DFS in grade 2nd and 3rd in Texas Scale. Ischemic wounds
before revascularization are a contraindication for this therapy.
To stop the infection from spreading, it is recommended to
change foam and gauze every 2–3 days. Special care is advised
while changing dressings to avoid in-grows of granulation
tissue into the dressing. Monitoring of morphology parameters
is indicated before and during the therapy. When lengthy
healing is observed, histopathological assessment is advised to
exclude malignancy. A comprehensive treatment of the patient
involving both standard methods and NPWT significantly
increases the chances of saving the affected limb.
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